TOPO THERAPEUTICS

Serial Number 98649268
686

Registration Progress

Application Filed
Jul 15, 2024
Under Examination
Approved for Publication
Feb 25, 2025
Published for Opposition
Feb 25, 2025
Registered

Basic Information

Serial Number
98649268
Filing Date
July 15, 2024
Published for Opposition
February 25, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
686
Status Date
Jul 7, 2025
Application
Pending
Classes
005 042

Rights Holder

Topo Therapeutics, Inc.

03
Address
1 Kendall Square
Building 1400w, Suite 14-101
Cambridge, MA 02139

Ownership History

Topo Therapeutics, Inc.

Original Applicant
03
Cambridge, MA

Topo Therapeutics, Inc.

Owner at Publication
03
Cambridge, MA

Legal Representation

Attorney
Susan Weller

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

21 events
Date Code Type Description
Jul 6, 2025 ETOP T EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Mar 26, 2025 ETOF T EXTENSION OF TIME TO OPPOSE RECEIVED
Feb 25, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 25, 2025 PUBO A PUBLISHED FOR OPPOSITION
Feb 19, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 30, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 30, 2025 GNEA F EXAMINERS AMENDMENT E-MAILED
Jan 30, 2025 XAEC I EXAMINER'S AMENDMENT ENTERED
Jan 30, 2025 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 30, 2025 CNEA R EXAMINERS AMENDMENT -WRITTEN
Jan 29, 2025 CNRT R NON-FINAL ACTION WRITTEN
Jan 29, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 29, 2025 GNRT F NON-FINAL ACTION E-MAILED
Jan 28, 2025 DOCK D ASSIGNED TO EXAMINER
Jan 15, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 21, 2024 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 21, 2024 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 21, 2024 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 21, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 21, 2024 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 15, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of pain disorders, folding disorders, and secretory diarrhea; pharmaceutical preparations, namely, a drug for the purpose of targeting ion channels and membrane transporters; pharmaceutical preparations, namely, a drug for the purpose of targeting ion channels and membrane transporters for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical preparations for the treatment of pain through activation of specific K+ channels in the peripheral nervous system; pharmaceutical preparations for the treatment of folding disorders via the detection of surface-expression of membrane proteins; pharmaceutical preparations for the purpose of limiting dehydration for patients suffering from secretory diarrhea; pharmaceutical preparations for the treatment of physiological diseases
Class 042
Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research for the purpose of treating pain disorders, folding disorders, and secretory diarrhea; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine

Additional Information

Translation
The English translation of the word "TOPO" in the mark is "mole".

Classification

International Classes
005 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"